Related Experiment Video
Updated: May 15, 2026

Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
Risk factors for increased left ventricular hypertrophy in patients with chronic kidney disease
Kosaku Nitta1, Satoshi Iimuro2, Enyu Imai3
1Department of Medicine, Kidney Center, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan. knitta@kc.twmu.ac.jp.
Insights
Left ventricular hypertrophy (LVH) affects over 20% of chronic kidney disease (CKD) patients. Key risk factors include cardiovascular disease history, high blood pressure, obesity, and low calcium levels.
Area of Science:
- Nephrology
- Cardiology
- Internal Medicine
Background:
- Left ventricular hypertrophy (LVH) is a known cardiovascular risk in chronic kidney disease (CKD).
- The prevalence and specific risk factors for LVH in predialysis CKD patients remain underexplored.
Purpose of the Study:
- To investigate the prevalence of LVH in predialysis CKD patients.
- To identify factors associated with increased left ventricular mass index (LVMI) in stages 3-5 CKD.
Main Methods:
- Cross-sectional analysis of 1185 participants from the Chronic Kidney Disease Japan Cohort (CKD-JAC) study.
- LVMI was measured, with LVH defined as LVMI >125 g/m² (males) or >110 g/m² (females).
- Multivariate logistic regression identified independent risk factors for LVH.
Main Results:
- LVH was present in 21.7% of the CKD cohort.
- Independent risk factors for LVH included prior cardiovascular disease, elevated systolic blood pressure, higher body mass index, and lower serum calcium levels.
- Diabetes mellitus was the underlying cause in 41.3% of patients.
Conclusions:
- Baseline data from the CKD-JAC study highlight significant associations between LVH and specific risk factors in predialysis CKD.
- Further longitudinal studies are necessary to determine the prognostic implications of LVH in this patient population.
Background:
Although left ventricular hypertrophy (LVH) has been established as a predictor of cardiovascular events in chronic kidney disease (CKD), the relationship between the prevalence of LVH and CKD stage during the predialysis period has not been fully examined.
Methods:
We measured left ventricular mass index (LVMI) in a cross-sectional cohort of participants in the Chronic Kidney Disease Japan Cohort (CKD-JAC) study in order to identify factors that are associated with increased LVMI in patients with stage 3-5 CKD. LVH was defined as LVMI>125 g/m2 in male patients and >110 g/m2 in female patients.
Results:
We analyzed baseline characteristics in 1185 participants (male 63.7%, female 36.3%). Diabetes mellitus was the underlying disease in 41.3% of patients, and mean age was 61.8±11.1 years. LVH was detected in 21.7% of patients at baseline. By multivariate logistic analysis, independent risk factors for LVH were past history of cardiovascular disease (odds ratio [OR] 0.574; 95% confidence interval [CI] 0.360-0.916; P=0.020), systolic blood pressure (OR 1.179; 95% CI 1.021-1.360; P=0.025), body mass index (OR 1.135; 95% CI 1.074-1.200; P<0.001), and serum calcium level (OR 0.589; 95% CI 0.396-0.876; P=0.009).
Conclusion:
Cross-sectional baseline data from the CKD-JAC study shed light on the association between LVH and risk factors in patients with decreased renal function. Further longitudinal analyses of the CKD-JAC cohort are needed to evaluate the prognostic value of LVH in CKD patients.
More Related Videos
Related Concept Videos
Chronic Kidney Disease I: Introduction
Chronic Kidney Disease IV: Nursing Management
Heart Failure II: Pathophysiology
Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease III: Interprofessional Care
Heart Failure Drugs: Diuretics

